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Abstract
Background and Objective Nearly 10 % of all US hospital
admissions are attributed to acute bacterial skin and skin
structure infections (ABSSSIs). While most antibacterials
used to treat these infections require multi-day and multi-
dose regimens, a single-dose treatment is now available. The
objective of this analysis is to estimate the annual budget
impact of using single-dose oritavancin in patients with
moderate to severe ABSSSIs receiving intravenous methi-
cillin-resistant Staphylococcus aureus (MRSA)-active
antibacterials from a US hospital perspective.
Methods A decision-analytic model based on current clin-
ical practice was developed to estimate the economic impact
of oritavancin. Utilization of antibacterials and rates of hos-
pital admission were derived from the Premier Research
Database. Demographic and clinical data were informed by
the published literature and 2014 wholesale drug acquisition
costs were used. Other costs were based on the published
literature and Medicare National Limitation amounts. All
costs were inflated to 2014 US dollars. Two base-case sce-
narios were considered: one for hospitals with ambulatory
services and one for hospitals without ambulatory services.
Results For a US hospital with ambulatory services with
1000 ABSSSI patients receiving intravenous MRSA antibi-
otics annually, use of oritavancin in 26 % of patients is esti-
mated to reduce the total annual budget by 12.9 %
(US$1.23 million), or approximately US$1234.67 per patient.
Total inpatient costs will be reduced by 22.3 %
(US$1.40 million) andoutpatient costswill increase slightly by
1.7 % (US$55,310). Pharmaceutical cost increases are offset
by savings in the inpatient setting from fewer hospital admis-
sions. Hospitals without ambulatory services are estimated to
receive overall cost savings of 9.3 % (US$0.63 million).
Conclusion Use of single-dose oritavancin in select
ABSSSI patients with suspected or confirmed MRSA
involvement is estimated to save US hospitals approxi-
mately 9.3–12.9 % per year by reducing hospital admis-
sions and lowering drug administration burden.
Key Points for Decisions Makers
Use of oritavancin in moderate to severe acute
bacterial skin and skin structure infections
(ABSSSIs) patients is expected to save hospitals
substantial costs by reducing hospital admissions and
decreasing costs associated with outpatient therapy.
Use of oritavancin may facilitate outpatient
treatment of ABSSSI, thereby reducing the cost and
resource use associated with hospital admissions.
Due to its single-dose administration, use of
oritavancin may eliminate the need for daily
intravenous drug administration and associated costs.
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1 Introduction
Management of patients with serious skin infections is a
major burden on the US healthcare system. The Centers for
Disease Control have reported that there are over
3.4 million emergency department (ED) visits annually for
cellulitis and abscesses, making skin infections the seventh
leading primary diagnosis seen in the ED [1]. Nearly 10 %
of all US hospital admissions are attributed to acute bac-
terial skin and skin structure infections (ABSSSIs), and
total US hospital costs for treating ABSSSI patients in
2010 alone were estimated to be more than US$6 billion
[2, 3]. ABSSSIs are predominantly caused by Gram-posi-
tive pathogens, with Staphylococcus aureus the most
prevalent organism [5]. In recent decades, methicillin-re-
sistant S. aureus (MRSA) strains have become increasingly
common and, if un- or under-treated, may become life-
threatening. The overall national prevalence of MRSA has
been reported to be 59 %; however, the rate varies by
hospital and geography and can reach up to 74 % or more
of cases [6]. The high volume of ED visits, hospital
admissions, and high costs require hospitals and healthcare
systems to ensure clinically effective and cost-effective
management of ABSSSI. Given the high prevalence of
MRSA, any agent used in an effort to reduce the healthcare
burden associated with treatment of ABSSSI must have
reliable activity and demonstrated efficacy against this
highly virulent pathogen [6].
Currently, the Infectious Diseases Society of America
(IDSA) guidelines and associated drug package inserts
recommend a treatment course of a minimum of 5–14 days
of antibacterials such as vancomycin, daptomycin, cef-
taroline, or intravenous/oral linezolid whether or not
MRSA has been confirmed [7–12]. The multi-dose and
multi-day treatment regimens required of most antibacte-
rial drugs leads to multi-day hospital stays and often
repeated visits to an infusion center to complete the course
of therapy following discharge.
Oritavancin (Orbactiv, The Medicines Company,
Parsippany, NJ, USA) is a recently approved intravenous
semi-synthetic lipoglycopeptide antibacterial indicated for
the treatment of adult patients with ABSSSI caused by
certain Gram-positive pathogens including MRSA [13]. As
the first and only US FDA-approved single-dose treatment
for ABSSSI, it has been hypothesized that oritavancin may
reduce costs for ABSSSI treatment through the avoidance
of hospitalization or shortened length of stay (LOS) made
possible by its once-only dosing, particularly in stable pa-
tients with moderate to severe ABSSSIs [4, 7]. To explore
this hypothesis, a budget impact model was developed
from the hospital perspective to estimate the economic
impact of using once-only oritavancin in moderate to
severe ABSSSI patients. The objective of the analysis was
to understand the cost impact of shifting an increased
proportion of patients to care in the ambulatory setting, as
compared to the current standard of care, based on
nationally representative practice patterns.
2 Methods
A decision-analytic model based on current clinical practice
was developed to simulate treatment of ABSSSI patients
receiving empiric treatment with MRSA-active antibacteri-
als (Fig. 1). The perspective of the model is from a US
hospital, and costs considered include the index treatment
episode and 30-day ABSSSI-related re-hospitalization. The
decision tree was developed based on literature review and
expert clinical opinion (SD, DPN, and TPL).
The model was used to estimate the annual budget
impact of using oritavancin for a hypothetical US hospital
with 1000 patients per year receiving intravenous MRSA-
active antibacterials for ABSSSI. Since incidence of the
disease varies by hospital, 1000 patients was selected as the
population in order to facilitate comparison with individual
hospitals. The base case reflects a nationally representative
empiric treatment mix of 92 % vancomycin, 2 % linezolid
intravenous, and 6 % daptomycin (Table 1). In the scenario
case, oritavancin was assumed to be used in 26 % of
patients, representing those patients with moderate to
severe ABSSSI who can safely be managed in an outpa-
tient environment, as derived from an analysis of the Pre-
mier Research Database [14]. In this analysis,
approximately 26 % of admitted patients with ABSSSIs
were Eron classification 2 and 3, a group of patients with
moderate to severe ABSSSI with the potential to receive
treatment in the outpatient setting due to lack of other
reasons for hospital admission. Oritavancin usage in this
scenario was assumed to displace vancomycin while all
other antibacterial use was unchanged, resulting in a sce-
nario treatment mix of 66 % vancomycin, 26 % orita-
vancin, 2 % linezolid intravenous, and 6 % daptomycin.
We elected to shift 26 % of patients from vancomycin to
oritavancin use rather than the other antibacterials for two
reasons. First, vancomycin was the clinical comparator in
the SOLO trials of oritavancin [15, 16]. In these trials,
oritavancin was shown to be non-inferior to vancomycin
for ABSSSI. Therefore, oritavancin will likely replace
vancomycin in clinical use due to the available comparator
data. Second, vancomycin was the least expensive of the
drugs included in this analysis. We thus felt that comparing
a new more costly alternative to the least expensive
established treatment was the most economically conser-
vative assumption. If oritavancin is found to be cost saving
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relative to vancomycin, it will also be cost saving relative
to linezolid and daptomycin. Based on expert clinical
opinion, oritavancin patients were assumed to be treated in
the following settings and frequencies: hospital inpatient
(5 %), observation (80 %), and outpatient (15 %). It was
assumed that 100 % of observation patients were dis-
charged to outpatient care.
In order to capture the experience of hospitals with and
without financial risk for outpatient care, two base-case
scenarios were assessed:
1. Hospital with ambulatory services. This represents a
hospital at full financial risk for the patients’ entire
course of care (e.g., patients return to a hospital-owned
setting for ambulatory treatment, such as a hospital-
owned outpatient parenteral antimicrobial therapy
[OPAT] infusion center). For these hospitals, outpa-
tient costs could accrue through hospital outpatient
departments such as the ED and observation unit as
well as in the ambulatory care setting, such as an
OPAT infusion center.
2. Hospital without ambulatory services. This represents
a hospital that bears 0 % of costs incurred outside the
inpatient setting (e.g., patients are discharged to an
independently owned ambulatory infusion setting,
such as a physician-owned OPAT infusion center or
a home health infusion agency). Patients in hospitals
without ambulatory services could still incur outpatient
costs in the ED or when they are under observation;
however, the costs and resource use associated with
continued ambulatory services provided outside of the
hospital would not accrue to the hospital budget.
2.1 Model Structure
As illustrated in Fig. 1, ABSSSI patients entering the ED
are treated with empiric MRSA-active therapy and may be
cultured for pathogen confirmation and susceptibility test-
ing. After receiving one dose of empiric therapy in the ED,
patients may be treated in one of three settings: hospital
inpatient, observation, or outpatient. The model includes
the following outcomes for responders: (1) continue
empiric therapy; (2) de-escalate therapy (including either
switching to non-MRSA active therapy, a less frequent
dosing regimen, or oral therapy); or (3) switch therapy due
Fig. 1 Decision-analytic framework for acute bacterial skin and skin
structure infection patient management. ABSSSI acute bacterial skin
and skin structure infection, AE adverse event, G? Gram-positive
pathogens, IV intravenous, MRSA methicillin-resistant Staphylococ-
cus aureus, PO oral
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to intolerance. Responders who de-escalate therapy are
assumed to continue to respond. Non-responders and
patients who discontinue due to intolerance require
switching to a second-line intravenous antibacterial, and
these patients are assumed to be cured following second-
line therapy. Patients who are placed under observation
may progress to treatment as inpatients or to discharge for
continued ambulatory treatment. Following clinical prac-
tice, admitted patients may complete their full course of
therapy in the hospital or they may be discharged to
complete their treatment as outpatients. For patients dis-
charged to outpatient from the ED or observational unit,
responders may continue therapy, de-escalate, or switch
intravenous antibiotic therapy due to adverse events (AEs).
Non-responding outpatients will require a switch of ther-
apy, and may then become hospitalized or kept as
outpatients, with or without a period of observation.
ABSSSI patients are followed up through the treatment
paradigm until 30 days after completion of therapy; 30-day
readmission rates specific to the final therapy were applied
for all patient pathways. Table 1 lists the key clinical
inputs used in the model.
2.2 Clinical Inputs
Clinical inputs were obtained from a systematic literature
review and network meta-analysis (NMA) [17]. In brief,
the NMA utilized Bayesian indirect treatment effects to
determine the comparative efficacy point estimates for
MRSA infections, non-MRSA infections, and unknown
infections for multiple antibacterials including van-
comycin, linezolid, daptomycin, oritavancin, and others.
Table 1 Key clinical inputs (%)
Utilization parameters Oritavancin Vancomycin Linezolid Daptomycin Source
Empiric treatment setting [19], expert opinion
Inpatient 5.0 55.9 77.0 19.0
Observation 80.0 66.0 7.0 1.0
Outpatient 15.0 33.5 16.0 80.0
Final treatment setting [19], expert opinion
Inpatient 5.0 22.6 28.0 35.0
Outpatient 95.0 77.4 72.0 65.0
Empiric therapy utilization rate (base case) 0.0 92.0 2.0 6.0 [19]
Empiric therapy utilization rate (scenario) 25.8 66.3 2.0 6.0 Assumption
Response rate [17]
MRSA 74.5 76.0 83.0 68.4
Non-MRSA 85.0 89.0 90.0 94.3
Unknown pathogen 82.9 82.2 87.4 90.2
Mortality [15, 16, 19, 33]
MRSA 0.4 0.9 0.4 0.4
Non-MRSA 0.4 0.9 0.4 0.4
Unknown pathogen 0.2 0.3 0.4 0.4
AE discontinuation 0.0 6.0 3.0 2.8 [10, 36, 37]
30-day ABSSSI-related readmission rate 1.6 3.0 4.0 4.2 [34, 35, 38, 39]
AE rates [10, 12, 13]
Elevated CPK 0.6 0.0 0.0 2.8
Myelosuppression 0.0 0.0 3.5 0.0
Acute kidney injury 0.0 1.0 0.0 0.0
Phlebitis 0.0 9.2 4.5 4.3
Rash/pruritus 3.0 6.0 2.0 4.5
Nausea/vomiting 7.3 7.6 5.0 5.2
Diarrhea 3.7 3.3 2.2 0.0
Constipation 3.4 3.9 0.0 2.4
ABSSSI acute bacterial skin and skin structure infections, AE adverse event, CPK creatine phosphokinase, MRSA methicillin-resistant Staphy-
lococcus aureus
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Discontinuation, relapse, and AEs were not reported sep-
arately by pathogen type, and thus a single estimate
informed by the literature search was used for each drug
across all pathogen types (Table 1).
2.3 Healthcare Resource Inputs
Data derived from the Premier Research Database were
used as the basis for determining the base-case first- and
second-line treatment mix, days of treatment (DOT), LOS,
and treatment setting for ABSSSI patients (Tables 1, 2)
[18]. The Premier Research Database is geographically
representative of the US and includes billing records for
approximately one out of every five hospital discharges
nationally [19]. Patients were included for analysis if they
had a primary diagnosis relating to one of the following
International Classification of Diseases, 9th revision,
Clinical Modification (ICD-9-CM) codes: 035 erysipelas;
681.x and 682.x (cellulitis/abscess); 686.8 and 686.9 (other
specified/unspecified local infections of skin and subcuta-
neous tissue); 958.3 (post-traumatic wound infection);
998.5x (post-operative infections); and an intravenous
MRSA-active antibacterial prescription. Outcomes
assessed include practice patterns for first- and second-
line treatment and, by therapy, the proportion of patients
treated as inpatients versus outpatients, total DOT, and
total LOS. As average LOS in the real world is not yet
known, an assumption of 2.5 days was used for orita-
vancin. Other intravenous antibacterial drugs had a ratio
of inpatient days to days of therapy that ranged from 0.3
to 0.4. If applied to oritavancin, it would result in an
unreasonable assumption of a less than 1-day stay. Con-
servatively, the assumption of 2.5 days of inpatient stay
was inputted for oritavancin.
Time spent in observation, required laboratory monitor-
ing and testing, drug administration frequency, and use of
peripherally inserted central catheter (PICC) lines were also
considered in the model. Published sources were used to
estimate an average of 17 h for observation stay; this value
was assumed to be equal across all treatments given lack of
available data to suggest otherwise [20, 21]. PICC lines were
assumed to be used in all patients receiving multi-day
infusions. Antibacterials were assumed to be administered
according to the prescribing information, and frequencies of
therapy-specific laboratory testing/monitoring were simi-
larly inferred. Baseline laboratory testing was not included,
as it was assumed to be equal for all patients. Table 2 lists
the key health resource inputs included in the model.
2.4 Economic Inputs
Economic inputs utilized for the model base-case scenario
are listed in Table 3. Published sources were used for PICC
line costs for patients requiring an indwelling catheter [22].
Given the lack of available US-based microcosting data,
Medicare National Limitation amounts were used as
proxies for the cost for observation care, laboratory and
drug administration costs, and hospital outpatient services.
Table 2 Key healthcare resources
Parameters Value Source





Laboratory tests (per week) [17, 40], expert opinion
Chem7 1 9 vancomycin; 1 9 daptomycin; 1 9 linezolid
CBC levels 1 9 linezolid
CPK levels 1 9 daptomycin
Drug trough concentrations 2 9 vancomycin
Hepatic panel 1 9 daptomycin
Length of stay for hospitalized patients discharged to outpatient treatment (days)
Oritavancin (IV) 2.5 Assumption
Vancomycin (IV) 4.1 [18]
Linezolid (IV) 4.42 [18]
Daptomycin (IV) 4.5 [18]
Average time in observation (h) 17.4 [20, 21]
CBC complete blood count, CPK creatine phosphokinase, IV intravenous
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AE costs were based on the drug and laboratory costs of
treating the condition. The Healthcare Cost and Utilization
Project’s (HCUP) 2011 National Inpatient Sample (NIS)
dataset, the largest publicly available all-payer hospital
inpatient care database in the US, was used to determine
the cost of nephrotoxicity (IDC-9-CM 584.8 [acute kidney
injury]). Costs associated with phlebitis were informed
from the literature [23]. Pharmaceutical acquisition costs
were based on the published wholesale acquisition cost
(WAC), as the average sale price is inconsistently reported
[24]. All costs were inflated to 2014 values using the
medical consumer price index as reported by the Bureau of
Labor Statistics [25].
2.5 Sensitivity Analysis
To assess the impact of uncertainty with model inputs on
the results, a univariate sensitivity analysis was conducted
where parameters were varied by ±20 % while keeping the
remaining inputs constant. The range of ±20 % was
selected as it would keep the inputs within plausible ranges
as seen in the literature and as advised by clinical experts.
For some parameters (e.g., response rate and others) where
the 20 % variation could not be feasibly applied, 100 %
was used for the upper range or 0 % (e.g., mortality and
others) as the lower range. Sensitivity analyses were con-
ducted using Oracle Crystal Ball Release 11.1.2.4 for
Table 3 Key economic inputs
Parameters Value (US$) Source
Drug acquisition costs









Drug trough concentrations 18.49
Hepatic panel 11.14
Drug administration costs
Peripherally inserted central catheter 412.15 [22]
IV infusion (initial hour) 172.18 [28]
IV infusion (each subsequent hour) 29.50
IV bolus push (2-min bolus) 105.90
Treatment setting cost per day
Observation cost 742.98 [28]
Inpatient cost 1231.81 [3]
Parameters Fixed costs (US$) Daily cost (US$) Source
AE costs
Hypokalemia 14.14 1.75 [22, 24, 28], expert opinion
Elevated CPK NA NA
Myelosuppression 26.21 NA






AE adverse event, CBC complete blood counts, CPK creatine phosphokinase, IV intravenous, PO orally
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Microsoft Office (Oracle Corporation, Redwood Shores,
CA, USA).
3 Results
3.1 Budget Impact Analysis
Figure 2 illustrates the total estimated annual hospital costs
for hospitals with (Fig. 2a) and without (Fig. 2b) ambula-
tory services.
3.1.1 Hospital with Ambulatory Services
For a hospital with ambulatory services, the annual budget
is expected to decrease from US$9.6 million in the base
case to US$8.3 million in the scenario, resulting in an
overall net savings of 13 %, or US$1.3 million
(US$1235/patient). The greatest savings came from inpa-
tient hospitalization, where costs were reduced by 22 %
from US$6.3 million to US$4.9 million (Fig. 2a). Hospi-
talization was the greatest total annual cost category driver
of cost reduction, followed by drug administration costs.
Hospitalization and drug administration costs were reduced
by 76 % (US$1.1 million) and 23 % (US$0.3 million),
respectively (Fig. 3a). Total pharmaceutical costs
increased 61 % from US$1 million in the base case to
US$1.6 million in the scenario due to the higher drug
acquisition costs associated with oritavancin (Fig. 3a).
Although more patients in the scenario were treated
entirely in an outpatient setting (47 % in the base case vs.
68 % in the scenario), total outpatient costs increased by
only 2 % (US$3.2 million to US$3.3 million). Total
patient days were reduced for both inpatient and outpatient
stays (inpatient: from 3629 to 2764 days; outpatient: from
6377 to 5087 days). Observation days increased from
43 days in the base case to 193 days in the scenario (data
not shown), which led to a slight increase in annual
observation unit costs of US$111,780 (Fig. 3a). The
number of laboratory tests was reduced by 4165 tests
(29 %) in the scenario because oritavancin patients do not
require monitoring. Other events such as readmissions
were slightly improved with greater use of oritavancin
(data not shown), largely through avoidance of any
admission due to its once-only dosing
3.1.2 Hospital Without Ambulatory Services
A hospital without ambulatory services is not financially at
risk for continued ambulatory treatment outside the hos-
pital. For these hospitals, the total annual cost is also
expected to decrease. The budget was reduced from
US$6.9 million in the base case to US$6.2 million in the
scenario, resulting in an overall net cost savings of 9 %, or
US$0.6 million (US$634/patient). The inpatient hospital-
ization costs and savings mirror those of hospitals with
ambulatory services, as given in Sect. 3.1.1, with inpatient
costs reduced by 22 % overall. Outpatient costs, including
costs associated with activities in the ED and observation
(but excluding continued ambulatory treatment costs),
increased by US$0.7 million (125 %), from US$0.5 mil-
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Fig. 2 Budget impact analysis for a US hospital with 1000 acute
bacterial skin and skin structure infection patients eligible for
intravenous methicillin-resistant Staphylococcus aureus-active
antibacterials: a total annual costs and budget impact by setting and
net savings for hospitals with ambulatory services; and b total annual
costs and budget impact by setting and net savings for hospitals
without ambulatory services. ED emergency department
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(Fig. 2b). The majority of this increase is due to the
increased drug acquisition costs associated with orita-
vancin (US$0.2 million in the base case to US$0.7 million
in the scenario) (Fig. 3b). Total patient days associated
with inpatient and observation care were as outlined above
(decrease of 865 inpatient days and increase of 150
observation days).
3.2 Sensitivity Analysis
Figure 4 and Table 4 illustrate the top 15 variables with the
highest impact on the model results. Results are shown for
hospitals with ambulatory services, though similar results
were seen for hospitals without ambulatory services (data
not shown). The model was most sensitive to the clinical
response rates of antibacterials used in the largest propor-
tions of patients in this analysis: oritavancin and van-
comycin. As use of oritavancin was generally cost saving
due to its once-only dosing and the shift of patients to the
outpatient setting, the model was also sensitive to the
proportion of patients receiving oritavancin, hospital cost
per diem, and the unit cost (WAC) of oritavancin. Toge-
ther, these five variables accounted for approximately 95 %
of variation in model outputs, with results ranging from
US$591,849 to US$1,861,825 in cost savings with use of
oritavancin in the base-case scenario. All other inputs have
a relatively small impact on the model results; inputs not
included in Fig. 4 had an impact of less than 1.5 % on the
total costs.
4 Discussion
This budget impact analysis was developed to assist hos-
pital decision makers in evaluating the economic impact of
using oritavancin in ABSSSI patients receiving empiric
treatment with intravenous MRSA-active antibacterials. On
average, a US hospital with ambulatory services and an
annual caseload of 1000 ABSSSI patients receiving intra-
venous MRSA-active antibacterials could expect to save
approximately 13 % per year by using oritavancin in
patients with moderate to severe ABSSSI (26 % of
ABSSSI patients [14]) in a predominantly outpatient set-
ting, equating to a per patient cost savings of US$1235.
Hospitals without ambulatory services could see similar,
though slightly lower, cost savings with an expected net
savings of 9 % (US$634 per patient).
While oritavancin has a comparable response rate to
other antibacterial drugs, its once-only dosing regimen
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Base Case Scenario 
Fig. 3 Total annual cost by cost category for a US hospital with 1000
acute bacterial skin and skin structure infection patients receiving
intravenous MRSA-active antibacterials: a total annual cost by cost
category for hospitals with ambulatory services; and b total annual
cost by cost category for hospitals without ambulatory services. For
the base case and scenario, pharmaceutical represents the drug
acquisition costs only for all antibacterials included in the model;
hospitalization is the cost of inpatient stay excluding costs associated
with pharmaceuticals, drug administration, laboratory tests, and
monitoring associated with MRSA-active antibacterials included in
the model, adverse events, and readmissions; drug administration is
the costs associated with drug administration, excluding pharmaceu-
tical acquisition costs; lab is the costs of laboratory tests and
monitoring associated with MRSA-active antibacterials included in
the model; AE is the cost associated with the adverse events listed in
Table 1; and readmission represents the costs associated with 30-day
re-hospitalization. AE adverse event, MRSA methicillin-resistant
Staphylococcus aureus
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altogether, with treatment entirely in the ED or observation
setting. While a portion of patients who do not respond to
initial oritavancin therapy may ultimately be hospitalized
(this was a clinical input for the model), the majority of
patients receiving other intravenous antibacterials receive
initial care in the hospital setting. The model results sug-
gest that the higher acquisition price of oritavancin than of
vancomycin is offset by reducing the total number of
hospital admissions, decreasing drug administration costs,
and reducing continued ambulatory infusions. Cost offsets
were seen in both the inpatient and the outpatient setting
through reduction in the need for repeated daily infusions
and eliminating the need for an indwelling catheter, which
also leads to fewer indwelling catheter complications.
Though the base-case model assumes all patients receiving
multi-day intravenous therapy received PICC lines, the
sensitivity analysis indicates variations in PICC line uti-
lization have a negligible (\1 %) impact on the hospital
budget. Savings were also realized through the simplified
dosing regimen (single intravenous dose of oritavancin)
and lack of drug monitoring and other lab tests.
Though several economic models in ABSSSI have been
previously published, few have incorporated both inpatient
and outpatient costs as illustrated here [23, 30–32]. The
strength of this model is therefore seen in the estimate of
total hospital costs across all settings, including observa-
tion, admission, and discharge to outpatient care. Of note,
no published health economic models were identified that
incorporate the cost of observation care, which is becoming
increasingly more common as hospitals strive to manage
costs and reduce the burden of unnecessary hospital
admissions. The model as described simulates a market
mix of the most utilized empiric intravenous MRSA-active
antibacterial agents and an expanded second-line treatment
mix incorporating de-escalation, AE switching, and non-
response. Many other models take a more narrow view
comparing two agents or a more limited second-line
armamentarium in specific patient scenario comparisons.
Due to these differences, the model described here may be
more representative of the total impact on the hospital
budget, rather than only on patients whose treatment
pathway mirrors the pathways selected in the other models.
The results produced by this model are in the range of
previously published cost estimates, lending additional
credibility to the estimated results [23, 30–32].
Another strength of this model is the use of direct
hospital cost estimates for most model inputs. The
majority of previously published models have focused on
payer costs as opposed to direct hospital costs, in part due































-$2.5M -$2.0M -$1.5M -$1.0M -$0.5M $0.0M
ORI clinical response rate (unknown pathogen)
VAN clinical response rate (unknown pathogen)
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DAP avg. days of therapy
VAN avg. days of therapy
VAN clinical response rate (MRSA)
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treatment)
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VAN clinical response rate (non-MRSA)
LIN avg. days of therapy
OBS cost per day
ORI clinical response rate (non-MRSA)
Net Cost Diﬀerence
+20% -20%
Fig. 4 Univariate analysis:
impact of a ±20 % change on
total estimated costs for
hospitals with ambulatory
services. Only the top 15 most
impactful variables on the total





LIN linezolid, OBS observation
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hospital costs. Often, Centers for Medicare & Medicaid
Services (CMS) reimbursement rates may be used as a
proxy for costs when estimating hospital costs [27]. Here,
published data on the actual direct costs of PICC lines
(US$413) were used, which were substantially lower than
the CMS reimbursement rates (US$850) [22, 28]. Using
reimbursement rates in this instance would have overes-
timated the actual hospital costs associated with PICC
line insertion. While reimbursement rates were used as
proxy costs for some model variables, they were used
sparingly in instances where applicable direct costs were
not available. Sensitivity analyses indicate that these
discrepancies were unlikely to have a substantial impact
on the overall cost savings estimated by the model. Time
and motion studies have been used in previous models to
reflect hospital costs for inputs such as drug administra-
tion, though none have been recently conducted in the US
[26, 29].
Several factors should be considered when interpreting
the findings of this analysis. A number of simplifying
assumptions were made in the development of the model
that may impact model results; however, these are con-
sistent with previously published decision-analytic models
[23, 26, 31–33]. Direct costs from Gram-negative
antibacterial coverage, additional concomitant medications
(aside from those required to treat AEs), radiologic studies,
and costs associated with use of isolation units were not
included in the model as this was assumed to be consistent
across all patients. Excluding these variables reduces the
estimated total costs equally across patients, but would be
unlikely to affect net budget impact. Some patients may
also require therapy beyond second-line in order to achieve
a successful clinical outcome. With the high response rates
of currently available antibacterials (80–90 %), it is esti-
mated that less than 4 % of patients will require a third-line
or later therapy. This figure is also in line with the reported
30-day readmission rate (3–4 %), which was demonstrated
to have only a small impact on the overall budget (Fig. 2)
[34, 35]. Costs associated with monitoring tests for patients
receiving oritavancin were not included as its prescribing
information does not indicate that monitoring is necessary.
However, sensitivity analysis reveals that even when costs
associated with oritavancin are increased by US$580, the
treatment remains cost saving, indicating that with addi-
tional costs for monitoring the drug would remain cost
saving. Finally, because of limited availability of data, it
was assumed that outpatient drug-switching patterns were
similar to those seen in the inpatient setting. This
assumption was validated by clinical experts, and was
considered unlikely to have a large impact on total budget
impact; however, the exact magnitude and direction of this
impact is unknown.
Table 4 Top 15 variables with the highest impact on net cost difference in univariate analysis
Input variable Net cost difference (US$) Input Input Input
Minimum Maximum Range Explained
variation (%)a
Min. Max. Base case
ORI clinical response rate (unknown
pathogen)
-591,840 -1,861,825 1,269,986 40.76 66.4 % 99.5 % 82.9 %
VAN clinical response rate (unknown
pathogen)
-635,984 -1,817,681 1,181,697 76.05 65.7 % 98.6 % 82.2 %
ORI utilization (scenario) -1,567,426 -886,239 681,186 87.77 20.60 % 30.90 % 25.75 %
INPAT cost per day -1,033,725 -1,419,940 386,215 91.54 US$985.45 US$1478.17 US$1231.81
ORI unit cost -1,039,294 -1,414,371 375,077 95.10 US$2320.00 US$3480.00 US$2900.00
DAP average days of therapy -1,107,094 -1,346,571 239,478 96.55 8.85 days 13.27 days 11.06 days
VAN average days of therapy -1,123,285 -1,330,380 207,095 97.63 8.14 days 12.22 days 10.18 days
VAN clinical response rate (MRSA) -1,144,245 -1,309,420 165,174 98.32 60.8 % 91.2 % 76.0 %
INPAT first-line days of therapy (for
patients who switch treatment)
-1,158,349 -1,295,807 137,458 98.80 2.40 days 3.60 days 3.00 days
VAN empiric INPAT treatment -1,157,945 -1,294,108 136,163 99.27 47 % 71 % 59 %
DAP unit cost -1,170,498 -1,283,167 112,669 99.59 US$283.78 US$425.66 US$354.72
VAN clinical response rate (non-MRSA) -1,202,037 -1,266,957 64,920 99.69 71.2 % 100.0 % 89.0 %
LIN average days of therapy -1,195,803 -1,257,862 62,060 99.79 10.98 days 16.46 days 13.72 days
OBS cost per day -1,204,582 -1,249,082 44,500 99.84 US$594.38 US$891.58 US$742.98
ORI clinical response rate (non-MRSA) -1,203,804 -1,247,151 43,347 99.89 68.0 % 100.0 % 85.0 %
DAP daptomycin, INPAT inpatient, LIN linezolid, Max. maximum, Min. minimum, MRSA methicillin-resistant Staphylococcus aureus, OBS observation,
ORI oritavancin, VAN vancomycin
a Explained variation is cumulative
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The economic impact of antibacterial resistance was not
considered for any drugs in this analysis. As is the case
with other antibacterial agents, the efficacy of oritavancin
may be impacted in the future by the development of
resistance. However, clinical studies to date have not
identified a high propensity for oritavancin resistance to
emerge among indicated organisms, a finding that may be
attributed to oritavancin’s multiple mechanisms of action.
Future emergence of resistance could change the economic
results presented here. The impact of oritavancin on hos-
pital-acquired infections (HAIs) is not included in this
analysis and may require additional analysis. With more
MRSA patients treated in the outpatient setting, it could be
hypothesized that the rate of HAI may decline, thus further
reducing costs. Additionally, with its single-dose admin-
istration, oritavancin may aid in improving quality mea-
sures such as reduced re-admissions from enhanced
compliance, which may lower costs and have additional
implications on reimbursement.
Other indirect costs and measures such as patient quality
of life, treatment satisfaction, work productivity, and
patient out-of-pocket costs were also excluded from this
analysis. Use of single-dose oritavancin and thus avoidance
of hospital admission and/or daily visits to the infusion
center may enable patients to return to their normal
activities of daily living sooner, potentially resulting in
improved satisfaction, better quality of life, and reduced
time and money costs of transport to and from an infusion
center. Patients may also be able to return to work sooner,
providing additional benefits to both patients and
employers.
5 Conclusions
This budget impact analysis demonstrates that use of ori-
tavancin in moderate to severe ABSSSI patients is expec-
ted to save hospitals substantial costs by reducing hospital
admissions and decreasing costs associated with outpatient
therapy. The positive economic impact holds regardless of
whether the hospital has outpatient infusion services. Due
to its single-dose administration, use of oritavancin may
eliminate the need for daily intravenous drug administra-
tion and its associated costs. Use of oritavancin may also
facilitate outpatient treatment of ABSSSI, thereby reducing
the cost and resource use associated with hospital
admissions.
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